Financial Performance - Net profit attributable to shareholders was ¥124,880,496.24, a decrease of 39.59% year-on-year[8]. - Operating revenue for the period was ¥1,010,151,349.28, down 10.10% compared to the same period last year[8]. - Basic earnings per share were ¥0.1001, reflecting a decrease of 39.59% year-on-year[8]. - The company's net profit for the first three quarters of 2019 reached ¥656,581,519.69, representing a 53.07% increase compared to the same period last year[25]. - Investment income increased significantly to ¥511,993,974.31, a 372.78% rise year-on-year, due to the change in accounting method for certain investments[25]. - The company's operating profit rose by 45.92% to ¥774,270,632.09, driven by higher investment income despite a decrease in gross profit margin[25]. - The total comprehensive income attributable to the parent company was CNY 201,138,781.85, compared to CNY 238,601,956.67 in the previous period, indicating a decrease in overall profitability[86]. - The net profit for the current period is approximately ¥109.51 million, representing a growth of 5.3% compared to ¥103.53 million in the previous period[91]. - The net profit attributable to the parent company for the current period is approximately ¥671.28 million, an increase of 48.8% from ¥450.88 million in the previous period[100]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥14,807,436,125.37, an increase of 8.44% compared to the end of the previous year[8]. - Non-current assets totaled ¥9,273,462,422.62, an increase of 15.1% from ¥8,055,062,473.35[62]. - Total liabilities decreased by 32.54% to ¥670,983,378.72, influenced by the reclassification of certain bonds to current liabilities[25]. - Current liabilities increased to ¥5,478,637,612.73, compared to ¥4,504,473,454.26, marking a rise of 21.6%[65]. - The company's equity attributable to shareholders rose to ¥6,834,565,368.94, up from ¥6,068,025,668.64, representing an increase of 12.6%[68]. - Total liabilities increased to CNY 4,557,432,820.89, compared to CNY 4,376,587,436.51 in the previous period, indicating a rise in financial obligations[78]. - Total assets reached approximately ¥13.66 billion, a decrease of ¥120.73 million compared to the previous period[137]. - Current assets totaled approximately ¥5.6 billion, with a slight decrease of ¥37.56 million from the previous period[137]. Cash Flow - The net cash flow from operating activities was ¥34,972,944.05, a significant decline of 90.43%[8]. - Cash flow from operating activities showed a net outflow of ¥151,455,011.02, a 130.64% decline compared to the previous year, attributed to increased cash payments for goods and services[29]. - The net cash flow from investing activities was negative at ¥638,696,357.83, a 79.58% increase in outflow year-on-year due to higher cash payments for equity investments[29]. - Cash flow from operating activities totaled 1,682,827,555.79 yuan, an increase from 1,308,163,122.91 yuan in the previous period, indicating improved operational performance[123]. - The cash flow from investment activities resulted in a net outflow of -1,923,296,357.10 yuan, compared to -1,547,193,114.80 yuan in the previous period, indicating increased investment expenditures[123]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 27,198[12]. - The largest shareholder, Shenzhen Le Ren Technology Co., Ltd., held 38.01% of the shares, totaling 474,029,899 shares[12]. - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[18]. - The company has committed to not engaging in any competitive business during the period of being a controlling shareholder[41]. Research and Development - Research and development expenses surged to CNY 54,048,691.20, compared to CNY 6,445,554.94 in the previous period, reflecting a significant increase in investment in innovation[79]. - Research and development expenses increased significantly to ¥18.67 million, up 112.5% from ¥8.79 million in the previous period[91]. - The company is advancing its clinical trials for the monoclonal antibody drug AR-301, which has received approval for Phase III trials from NMPA and is also undergoing trials in the US and Europe[30]. - The company continues to advance the RVX-208 project based on the clinical trial results, with major clinical outcomes to be announced at the American Heart Association meeting[33]. Financial Instruments and Standards - The company executed new financial instrument standards, leading to various reclassifications in financial assets[23]. - The company has implemented new financial instrument standards effective from January 1, 2019, impacting the classification of certain financial assets[147].

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2019, representing a year-on-year increase of 15%[19]. - The net profit attributable to shareholders was RMB 300 million, up 20% compared to the same period last year[19]. - The company has set a revenue guidance of RMB 2.5 billion for the full year 2019, reflecting a growth target of 10%[19]. - The company's operating revenue for the reporting period was ¥2,128,873,735.18, a decrease of 3.00% compared to the adjusted revenue of ¥2,194,827,009.11 from the same period last year[26]. - Net profit attributable to shareholders was ¥546,402,001.38, representing a significant increase of 144.08% compared to the adjusted net profit of ¥223,863,667.30 from the previous year[26]. - The company achieved total operating revenue of RMB 2,128,873,735.18, a decrease of 3.00% compared to the same period last year[66]. - The company reported a total of RMB 1.14 billion in stock investments, with a fair value loss of RMB 17.15 million[94]. - The company achieved a net profit of 190.6 million yuan for the reporting period, fulfilling its performance commitment[136]. Research and Development - Research and development expenses increased by 30% to RMB 150 million, focusing on innovative drug formulations and delivery systems[19]. - The company implemented 3 self-initiated R&D projects and is currently applying for 8 invention patents, with 5 patents granted[65]. - The company is actively transforming towards innovative drug development, focusing on cardiovascular and oncology treatments[65]. - The company is investing heavily in new drug development, with multiple candidates in clinical stages, but acknowledges the inherent risks and uncertainties in the process[129]. Market Expansion and Product Development - The company plans to expand its product line with the introduction of three new drugs by the end of 2019, targeting a market size of approximately RMB 500 million[19]. - User data indicates a 25% increase in the number of active customers, reaching 1.5 million by June 2019[19]. - The company is exploring potential mergers and acquisitions to enhance its market presence, particularly in the Asia-Pacific region[19]. - The company is actively expanding its market presence in the EU, with market share increases in regions such as the UK, Poland, and Italy[61]. - The company plans to expand its production capacity and enhance its market presence through strategic acquisitions and investments in biotechnology firms[111]. Financial Position and Investments - The net cash flow from operating activities was -¥186,427,955.07, a decline of 224.86% compared to the previous year's cash flow of ¥149,309,948.36[26]. - The cash and cash equivalents decreased by 32.83% at the end of the reporting period, primarily due to the payment for the acquisition of Duople[49]. - The company approved a merger loan application of up to RMB 1.2 billion from China Merchants Bank, with a term not exceeding 5 years, to finance the acquisition of 100% equity in Duople[85]. - The total investment amount during the reporting period reached RMB 706.86 million, a significant increase of 266.66% compared to RMB 192.79 million in the same period last year[86]. - The company reported a total derivative investment of 43,154 million CNY, with a net loss of 511.5 million CNY during the reporting period[99]. Compliance and Regulatory Matters - The management highlighted the importance of regulatory compliance and quality assurance in maintaining competitive advantage in the pharmaceutical industry[19]. - The company’s subsidiary, Chengdu Shenrui, received GMP certification from the Italian drug regulatory authority, indicating compliance with EU GMP standards[61]. - The newly built enoxaparin sodium production line by Tiandao Pharmaceutical received GMP certification from the Polish drug regulatory authority, enhancing production capacity[61]. - The company has maintained compliance with all commitments made during the reporting period[145]. Environmental and Social Responsibility - The wastewater treatment facility has a design capacity of 30 tons/day, upgraded from the original 20 tons/day, and passed environmental acceptance on April 16, 2015[179]. - The company has implemented pollution prevention measures in accordance with the "Three Simultaneities" principle, ensuring emissions are below the approved total[179]. - The total emissions of COD were 0.034569 tons/year, BOD 0.0957168 tons/year, and total phosphorus 0.000160425 tons/year, all below the permitted limits[175]. Employee and Corporate Governance - The company has a total of 20,618,035 shares under the second employee stock ownership plan, accounting for 1.65% of the total share capital[151]. - The company’s employee stock ownership plans have been executed as planned, with a lock-up period for the second plan ending on March 10, 2018[151]. - The company has not faced any major litigation or arbitration matters during the reporting period[149].

Financial Performance - The company's operating revenue for Q1 2019 was ¥1,023,118,395.29, representing a 6.65% increase compared to ¥798,062,177.39 in the same period last year[8]. - Net profit attributable to shareholders was ¥507,033,390.57, a significant increase of 636.43% from ¥41,988,171.45 in the previous year[8]. - The basic earnings per share rose to ¥0.4065, up 636.41% from ¥0.0337 in the same period last year[8]. - Total revenue increased significantly to 580,828,899.53, up 469.56% compared to the previous year[24]. - Net profit reached 494,548,778.62, representing a 593.02% increase year-over-year[24]. - Operating profit surged to 580,555,945.28, a 477.51% increase from the same period last year[24]. - The total comprehensive income for the current period was ¥483,170,110.98, compared to a loss of ¥65,759,857.72 in the previous period, showing a significant turnaround[81]. Cash Flow - The net cash flow from operating activities was -¥138,180,573.42, worsening by 80.53% compared to -¥48,225,972.78 in the previous year[8]. - Cash flow from operating activities decreased to -138,180,573.42, a decline of 80.53% compared to the previous year[24]. - Cash flow from investing activities also fell to -99,612,740.75, down 51.61% year-over-year[24]. - Cash flow from financing activities saw a significant drop to -593,869,140.67, a decrease of 574.54% compared to the previous year[24]. - The net increase in cash and cash equivalents was -837,713,560.20, reflecting a 3041.64% decline year-over-year[24]. - The ending balance of cash and cash equivalents was 1,280,195,092.57, down from 3,564,354,461.78 in the previous period[96]. Assets and Liabilities - Total assets at the end of the reporting period were ¥13,443,223,483.47, a decrease of 1.55% from ¥13,655,079,889.35 at the end of the previous year[8]. - The company's cash and cash equivalents decreased by 39.66% to CNY 1,280,300,092.57 due to repayment of bank loans and investment payments[22]. - The company's total liabilities decreased significantly by 98.51% to CNY 7,234,558.72 due to repayment of bank loans[22]. - Total liabilities decreased from CNY 7,410,333,285.80 to CNY 6,703,225,478.54, a reduction of approximately 9.5%[62]. - Total equity increased from CNY 6,244,746,603.55 to CNY 6,739,998,004.93, reflecting an increase of approximately 7.9%[64]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,804[12]. - The top shareholder, Shenzhen Lerun Technology, held 38.01% of the shares, totaling 474,029,899 shares[12]. - The company completed the issuance of non-public corporate bonds, raising a total of 700 million RMB with a final coupon rate of 5.5%[30]. Investments and Expenditures - Long-term equity investments increased by 142.30% to CNY 1,132,230,071.26 as a result of losing control over Junshengtai and adjusting the remaining equity value[22]. - Research and development expenses decreased by 35.08% to CNY 39,576,899.12, attributed to reduced R&D costs at subsidiary Tiandao Pharmaceutical[22]. - The company has made significant investments in equity partnerships, totaling 286.8 million RMB and 340.8 million RMB in various investment funds[38]. Future Plans and Strategies - The company plans to focus on market expansion and new product development as part of its future strategy[82].

Financial Performance - The company reported a total revenue of RMB 1,247,201,704 for the year 2018, marking a year-on-year increase of 15%[6]. - The company's operating revenue for 2018 was CNY 4,814,965,143.62, representing a 69.34% increase compared to the previous year[26]. - Net profit attributable to shareholders for 2018 was CNY 616,193,781.39, a significant increase of 213.33% year-over-year[26]. - The net profit after deducting non-recurring gains and losses reached CNY 420,508,823.39, marking a 929.45% increase compared to the previous year[26]. - Basic earnings per share for 2018 was CNY 0.4941, up 213.32% from CNY 0.1577 in 2017[28]. - Total assets at the end of 2018 were CNY 13,655,079,889.35, a decrease of 3.29% from the previous year[28]. - The weighted average return on equity for 2018 was 9.14%, an increase of 6.69% compared to 2017[28]. - The company's net profit attributable to ordinary shareholders for 2018 was 616,193,781.39 yuan, with a dividend payout ratio of 20.24%[172]. - Cash dividend amount is CNY 124,720,170.40, representing 6.43% of the distributable profit of CNY 1,940,094,058.22[173]. Investment and Acquisitions - The company completed a cash acquisition of 100% equity in Shenzhen Duople Industrial Development Co., Ltd., which required retrospective adjustments to the financial statements[31]. - The company completed the acquisition of 100% of Duopule, enhancing its capabilities in the enoxaparin raw material and formulation sectors[46]. - The company has committed to an investment project for the annual production of 50 trillion units of heparin sodium raw materials, with a total investment of CNY 29,312.3 million[119]. - The company has invested CNY 71,529.57 million in the heparin project as of December 31, 2016, indicating a significant investment commitment[122]. - The company completed the acquisition of Shenzhen Duople Industrial Development Co., Ltd. shares amounted to CNY 120,000 million, with a near-complete investment of CNY 119,999.99 million[123]. - The company has reported a realized benefit of CNY 36,230.19 million from its investment activities during the reporting period[123]. Market Expansion and Product Development - The company is focusing on expanding its market presence and enhancing its product portfolio through strategic acquisitions and partnerships[6]. - Future outlook indicates a commitment to research and development, particularly in new drug formulations and technologies[6]. - The company is exploring international markets, particularly in Europe and North America, to diversify its revenue streams[6]. - The company has established a pipeline of innovative drugs through investments, acquisitions, and collaborations, with several candidates in preclinical and clinical stages[160]. - The company aims to become a global leader in the heparin industry while expanding its innovative drug pipeline focused on oncology and cardiovascular diseases[151]. Research and Development - The company is actively transitioning towards innovative drug development, establishing a pipeline of products in various clinical trial stages, which supports future business growth[51]. - The company has completed two out of six R&D projects and holds 11 pending patents and 6 authorized patents[62]. - Research and development expenses increased by 99.76% to CNY 186,852,629.89 due to the integration of Junshentai and increased R&D costs[87]. - The number of R&D personnel increased by 52.94% to 208, with R&D investment amounting to CNY 189,608,536.36, which is 3.94% of operating revenue[93]. Risk Management - The company has identified key risks for future development and outlined corresponding mitigation strategies in its annual report[6]. - The company is exposed to foreign exchange risks due to significant exports and overseas subsidiaries, and it employs financial instruments to manage these risks[164]. - The company is committed to increasing quality control measures to mitigate product quality risks associated with complex production processes[157]. Operational Efficiency - The company plans to enhance its production capacity to meet growing demand, with an investment of RMB 200 million in new facilities[6]. - The company has developed a comprehensive quality management system in compliance with GMP standards, ensuring product quality stability and safety[47]. - The management transformation includes process optimization and the implementation of information technology to enhance operational efficiency[63]. Customer Engagement and Sales - User data shows a significant increase in customer engagement, with a 20% rise in active users compared to the previous year[6]. - The sales of raw materials amounted to ¥3,030,781,231.01, representing 62.95% of total revenue, with a growth rate of 57.59% compared to the previous year[69]. - International sales accounted for ¥4,351,289,560.36, which is 90.37% of total revenue, reflecting a growth of 78.53% year-on-year[69]. Dividend Policy - The profit distribution plan approved by the board includes a cash dividend of RMB 1.00 per 10 shares, totaling RMB 124,720,170.40[6]. - The cash dividend distribution plan complies with the requirement that cash dividends should account for at least 40% of the profit distribution total[173]. - The company’s cash dividend policy has been consistent, with no changes in the past three years, ensuring shareholder interests are protected[166].

深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告正文 证券代码：002399 证券简称：海普瑞 公告编号：2018-086 深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告正文 1 深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人李锂、主管会计工作负责人张斌及会计机构负责人(会计主管人 员)张斌声明：保证季度报告中财务报表的真实、准确、完整。 2 深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 √ 是 □ 否 追溯调整或重述原因 同一控制下企业合并 | | 本报告期末 | | | 上年度末 | | | 本报告期末比上年度 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | ...

Financial Performance - The company's operating revenue for the first half of 2018 was CNY 2,004,354,083.30, representing a 90.88% increase compared to CNY 1,050,040,613.07 in the same period last year[18]. - Net profit attributable to shareholders reached CNY 219,095,060.68, a significant increase of 2,840.84% from CNY 7,450,092.37 in the previous year[18]. - The net profit after deducting non-recurring gains and losses was CNY 209,990,505.16, compared to a loss of CNY 3,816,732.23 in the same period last year, marking a 5,601.84% increase[18]. - Basic earnings per share increased to CNY 0.176, up 2,833.33% from CNY 0.006 in the same period last year[18]. - The company achieved total revenue of 2,004.35 million yuan, an increase of 90.88% compared to the same period last year[55]. - Net profit reached 201.44 million yuan, a significant increase of 16,493.62% year-on-year, with net profit attributable to shareholders at 219.10 million yuan, up by 2.84 million yuan[55]. Cash Flow and Assets - The net cash flow from operating activities was CNY 75,793,760.69, a turnaround from a negative cash flow of CNY 172,930,337.36 in the previous year, reflecting a 143.83% improvement[18]. - The company reported a significant decrease in cash and cash equivalents, which fell to ¥2,055,549,077.32, down from ¥4,089,814,242.23 in the same period last year, primarily due to a payment of ¥1.224 billion for the acquisition of Duople[66]. - Total assets at the end of the reporting period were CNY 13,197,309,660.50, a slight increase of 0.06% from CNY 13,189,413,531.98 at the end of the previous year[18]. - Cash and cash equivalents decreased from CNY 3,495,559,006.61 to CNY 2,055,549,077.32[192]. - Total current assets decreased from CNY 5,819,833,756.17 to CNY 4,697,897,100.30, a decline of approximately 19.3%[197]. Business Operations - The company's main business is the production and sales of heparin sodium raw materials, accounting for over 70% of total revenue[26]. - Enzyme raw materials and biopharmaceutical CDMO businesses contributed 9.57% and 9.89% to revenue respectively in the first half of 2018[26]. - The sales volume and price of heparin raw materials increased significantly, leading to rapid revenue growth[33]. - SPL's enzyme raw materials sales volume and price both increased, with potential for new profit growth if FDA approval is obtained for a new drug[34]. - The company is transitioning towards becoming an innovative drug research and development enterprise, with multiple products expected to enter international multi-center clinical trials[36]. Investments and Acquisitions - The company completed the acquisition of 100% equity in Duople, with a cash transaction amounting to 240,000 million yuan, reflecting a significant investment in expanding its market presence[125]. - The company has invested RMB 120,000 million to acquire 100% equity of Shenzhen Duople Industrial Development Co., Ltd., with RMB 119,530.81 million already paid as of June 30, 2018[90]. - The company has ongoing significant non-equity investments in the biopharmaceutical sector, with total investments reaching ¥135,546,000 as of the reporting period[75]. - The company is actively expanding its production lines, with increased investments in the Ping Shan Pharmaceutical Park and subsidiaries, contributing to a rise in construction in progress to ¥852,863,603.00[66]. Risk Management - The company has outlined its major risks and corresponding countermeasures in the report, emphasizing the importance of risk awareness for investors[4]. - The company faces risks related to product quality, market competition, rising costs, new drug development failures, investment losses, and exchange rate fluctuations[101][102][104][105][106]. Shareholder and Governance - The company plans not to distribute cash dividends or issue bonus shares[5]. - The company has implemented an employee stock ownership plan, completing the purchase of 20,618,035 shares, which accounts for 1.65% of the total share capital[120]. - The major shareholders include Shenzhen Le Ren Technology Co., Ltd. with a 38.01% stake (474,029,899 shares) and Urumqi Jintian Soil Equity Investment Partnership with a 32.72% stake (408,041,280 shares)[158]. Environmental Compliance - The company strictly adheres to environmental regulations, ensuring pollutants are discharged in compliance with legal standards[137]. - The total COD discharge was 35 tons/year, with no exceedance of the permitted discharge limits[138]. - The company has no significant environmental pollution issues reported during the period[137]. Financial Management - The company has maintained a long-term credit rating of AA+ with a stable outlook from the rating agency, indicating strong creditworthiness[174]. - The bond proceeds have been managed in accordance with the commitments outlined in the bond prospectus[178]. - The company executed all commitments related to the bond issuance prospectus during the reporting period[186].

2017 年年度报告 2018 年 04 月 1 深圳市海普瑞药业集团股份有限公司 2017 年年度报告全文 深圳市海普瑞药业集团股份有限公司 深圳市海普瑞药业集团股份有限公司 2017 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人李锂、主管会计工作负责人张斌及会计机构负责人(会计主管人 员)张斌声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本年度报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺。 投资者及相关人士均应对此保持足够的风险认识，并且应当理解计划、预测与 承诺之间的差异。 公司已在本报告中详细描述未来将面临的主要风险及应对措施，详情请查 阅本报告"第四节 经营情况讨论与分析"之"九、公司未来发展的展望"部分，请 投资者注意投资风险。 公司经本次董事会审议通过的利润分配预案为：以 1,247,201,704 为基数， 向全体股东每 10 股派发现金红利 0.45 元（含税），送红股 ...

深圳市海普瑞药业集团股份有限公司 2018 年第一季度报告全文 深圳市海普瑞药业集团股份有限公司 2018 年第一季度报告 2018 年 04 月 1 深圳市海普瑞药业集团股份有限公司 2018 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人李锂、主管会计工作负责人张斌及会计机构负责人(会计主管人 员)张斌声明：保证季度报告中财务报表的真实、准确、完整。 2 深圳市海普瑞药业集团股份有限公司 2018 年第一季度报告全文 第二节 公司基本情况 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 798,062,177.39 | 455,637,144.25 | 75.15% | | 归属于上市公司股东的净利润（元） | 41,988,171.45 | -12,081, ...

深圳市海普瑞药业集团股份有限公司 2017 年年度报告全文 第一节 重要提示、目录和释义 深圳 圳市海普瑞药业 业集团股份有限 公司 2017 年年度报告全文 深圳市海普瑞药 药业集团 团股份有 有限公司 2017 7 年年度 度报告 201 18 年 04 4 月 1 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 2 | 目录 | | --- | 公司负责人李锂、主管会计工作负责人张斌及会计机构负责人(会计主管人 员)张斌声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 | 第一节 | 重要提示、目录和释义 6 | | --- | --- | | 第二节 | 公司简介和主要财务指标 10 | | 第三节 | 公司业务概要 13 | | 第四节 | 经营情况讨论与分析 34 | | 第五节 | 重要事项 52 | | 第六节 | 股份变动及股东情况 58 | | 第七节 | 优先股相关情况 58 | | 第八节 | 董事、监事、高级管理人员和员工情况 59 | ...

深圳市海普瑞药业集团股份有限公司 2017 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 证券代码：002399 证券简称：海普瑞 公告编号：2017-105 深圳市海普瑞药业集团股份有限公司 2017 年第三季度报告正文 1 深圳市海普瑞药业集团股份有限公司 2017 年第三季度报告正文 公司负责人李锂、主管会计工作负责人张斌及会计机构负责人(会计主管人 员)张斌声明：保证季度报告中财务报表的真实、准确、完整。 2 深圳市海普瑞药业集团股份有限公司 2017 年第三季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 13,123,584,725.29 | 12,913,585,939.92 | ...